RGEN

Repligen Corp. 10-Q Summary: Quarter Ended September 30, 2000

Business Context and Reporting Period

This is an unaudited quarterly report (Form 10-Q) for Repligen Corporation for the period ended September 30, 2000. Repligen is a biotechnology company developing therapeutic products for pediatric diseases, including autism (Secretin) and immune system disorders (CTLA4-Ig), as well as manufacturing products for antibody purification (Protein A). The company operates as a single segment with significant revenue concentration in the United States (83% for the six months ended Sept 30, 2000).

Key Financial Metrics

Cash Flow (Six Months): Net cash used in operating activities was $(1,210,946). Net cash provided by investing activities was $2,861,121 (primarily from redemption of marketable securities). Net cash provided by financing activities was $495,499 (from warrant and option exercises).

Material Changes vs. Prior Period

• Revenue: Total revenue increased 4% ($35,000) for the quarter and 31% ($520,000) for the six months compared to the prior year periods. This growth was driven by a 254% increase in investment income due to higher cash balances from a March 2000 private placement.
• Product Revenue: Decreased 44% ($255,000) for the quarter due to the timing of large Protein A orders, though it increased 9% year-to-date.
• R&D Revenue: Decreased 43% for the quarter and 63% year-to-date due to the discontinuation of government-sponsored research programs.
• Expenses: Total expenses increased 25% for the quarter and 51% year-to-date. R&D expenses surged 83% for the quarter and 99% year-to-date, driven by clinical trial expansion for Secretin and CTLA4-Ig and non-cash charges for warrant issuance.
• Liquidity: Cash and equivalents increased by $2.1 million during the six-month period, ending at $27.4 million. Total liquid assets (cash + marketable securities) totaled approximately $33.2 million.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management believes current funding is sufficient to meet working capital and capital expenditure requirements for the next 24 months. No specific financial guidance was provided.
• Clinical Progress: The FDA approved the initiation of a Phase II clinical trial for CTLA4-Ig in stem cell transplant patients in October 2000. The company is also pursuing FDA approval for synthetic Secretin products.
• Legal Proceedings: Repligen and the University of Michigan filed a complaint against Bristol-Myers Squibb (BMS) regarding inventorship of patents related to CTLA4. Failure to obtain shared ownership could restrict Repligen's ability to commercialize CTLA4-Ig.
• Accounting Changes: The company is evaluating the impact of SAB No. 101 regarding revenue recognition for upfront fees in alliances, though no significant impact is currently expected.
• Unusual Items: A non-cash charge of $183,750 was recorded for the acquisition of a patent application from Tolerance Therapeutics LLC. Additionally, non-cash charges related to stock and warrant issuance totaled $218,735 for the six-month period.

Investor Verification Checklist

• Patent Litigation Status: Verify the progress of the lawsuit against Bristol-Myers Squibb regarding CTLA4-Ig inventorship, as this is critical to the commercialization of a lead product.
• Product Revenue Volatility: Monitor the timing of Protein A orders, as revenue is heavily dependent on large, sporadic production scale orders.
• Clinical Trial Results: Track the outcomes of the Phase II trial for CTLA4-Ig and the FDA review status of the synthetic Secretin products.
• Burn Rate vs. Cash Reserves: Confirm that the $33.2 million in liquid assets remains sufficient to fund operations for the projected 24-month runway given the high R&D spend.
• Customer Concentration: Note that two customers accounted for 24% of revenue in the quarter ended Sept 30, 2000, creating concentration risk.